mTOR inhibition improves fibroblast growth factor receptor targeting in hepatocellular carcinoma

BACKGROUND: Systemic therapy has proven only marginal effects in hepatocellular carcinoma (HCC) so far. The aim of this study was to evaluate the effect of targeting fibroblast growth factor receptor (FGFR) on tumour and stromal cells in HCC models. METHODS: Human and murine HCC cells, endothelial c...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Br J Cancer
Main Authors: Scheller, T, Hellerbrand, C, Moser, C, Schmidt, K, Kroemer, A, Brunner, S M, Schlitt, H J, Geissler, E K, Lang, S A
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group 2015
Assuntos:
Translational Therapeutics
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4453944/
https://ncbi.nlm.nih.gov/pubmed/25688743
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2014.638
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados